CS
RCKT icon

Credit Suisse’s Rocket Pharmaceuticals RCKT Stock Holding History

Credit Suisse’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.41M Sell
89,280
-18
-0% -$511 ﹤0.01% 1731
2023
Q4 		$2.68M Buy
89,298
+13,745
+18% +$303K ﹤0.01% 1712
2023
Q3 		$1.55M Sell
75,553
-12,043
-14% -$219K ﹤0.01% 1991
2023
Q2 		$1.74M Buy
87,596
+16,865
+24% +$341K ﹤0.01% 2008
2023
Q1 		$1.21M Buy
70,731
+5,256
+8% +$103K ﹤0.01% 2210
2022
Q4 		$1.28M Buy
65,475
+34,321
+110% +$632K ﹤0.01% 2166
2022
Q3 		$497K Sell
31,154
-67
-0.2% -$1.04K ﹤0.01% 2778
2022
Q2 		$429K Buy
31,221
+876
+3% +$10.4K ﹤0.01% 2942
2022
Q1 		$481K Buy
30,345
+2,043
+7% +$35.3K ﹤0.01% 3004
2021
Q4 		$618K Buy
28,302
+1,643
+6% +$44.8K ﹤0.01% 3663
2021
Q3 		$797K Buy
26,659
+2,106
+9% +$76.7K ﹤0.01% 3516
2021
Q2 		$1.09M Buy
24,553
+30
+0.1% +$1.3K ﹤0.01% 3318
2021
Q1 		$1.09M Sell
24,523
-145
-0.6% -$7.96K ﹤0.01% 3267
2020
Q4 		$1.35M Sell
24,668
-43,978
-64% -$1.6M ﹤0.01% 3109
2020
Q3 		$1.57M Buy
68,646
+30,089
+78% +$741K ﹤0.01% 2610
2020
Q2 		$807K Buy
+38,557
New +$695K ﹤0.01% 3025
2020
Q1 		– Sell
-49,289
Closed -$1.12M – 4194
2019
Q4 		$1.12M Sell
49,289
-22,106
-31% -$369K ﹤0.01% 3037
2019
Q3 		$831K Buy
71,395
+19,637
+38% +$244K ﹤0.01% 3136
2019
Q2 		$776K Buy
51,758
+35,027
+209% +$611K ﹤0.01% 3117
2019
Q1 		$294K Sell
16,731
-11,034
-40% -$174K ﹤0.01% 3602
2018
Q4 		$411K Buy
27,765
+17,880
+181% +$297K ﹤0.01% 3357
2018
Q3 		$244K Sell
9,885
-7,605
-43% -$165K ﹤0.01% 3597
2018
Q2 		$343K Buy
+17,490
New +$331K ﹤0.01% 3580
2017
Q1 		– Sell
-3,755
Closed -$91K – 4013
2016
Q4 		$91K Buy
3,755
+128
+4% +$3.65K ﹤0.01% 3961
2016
Q3 		$138K Buy
3,627
+70
+2% +$2.2K ﹤0.01% 3880
2016
Q2 		$106K Sell
3,557
-9,069
-72% -$319K ﹤0.01% 4044
2016
Q1 		$374K Buy
12,626
+8,441
+202% +$253K ﹤0.01% 3402
2015
Q4 		$189K Buy
+4,185
New +$182K ﹤0.01% 3913

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's RCKT Position: Q1 2024 in Review

Credit Suisse reduced its Rocket Pharmaceuticals (RCKT) stake by 0.02% in Q1 2024, selling an estimated $511 and leaving 89,280 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Credit Suisse first reported a position in RCKT in Q4 2015 and has held it in 28 quarters since. The position peaked at $2.68M in Q4 2023. 186 funds tracked by Wall St. Rank hold RCKT as of Q1 2024.

  • Credit Suisse held 89,280 shares of Rocket Pharmaceuticals worth $2.41M as of Q1 2024.
  • Credit Suisse sold 18 Rocket Pharmaceuticals shares in Q1 2024, an estimated $511.
  • Rocket Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1731 holding.
  • Credit Suisse first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • Credit Suisse's Rocket Pharmaceuticals position peaked at $2.68M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.